Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) - NCT00798538-06510 (Clinical Trial 255383)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy255383.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
New Haven |
|
State:
|
|
CT |
| Zip Code: |
|
06510 |
| Conditions: |
|
Buprenorphine - HIV - Drug Abuse - Drug Addiction - Drug Dependence - Drug Use Disorders - Drug Use Disorder - Substance Abuse - Opiate Addiction - Substance-Related Disorders |
| Purpose: |
|
The purpose of this study is to assess the feasibility, cost and effectiveness of
interventions designed to integrate buprenorphine treatment for opioid dependence into HIV
primary care in ten HIV care centers in the U.S.
In the site led by Dr. Altice, we compare two models of providing HIV care and buprenorphine
treatment. Assignments are based on participants' city of residence. In the onsite
(integrated care) model, participants receive buprenorphine, substance abuse counseling and
HIV care at one location: the Waterbury Hospital Infectious Disease Clinic. In the off-site
model (non-integrated care) buprenorphine induction, substance abuse counseling, and HIV
care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale
AIDS Program, and patients' own HIV providers, respectively. Data is collected from
interviews with participants, reviews of medical records, and surveys and interviews with
clinicians.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- HIV-infected
- Clinical diagnosis of opioid dependence
- Fluent in English or Spanish
- 18 years or older
Exclusion Criteria:
- Liver function tests (transaminase only) at five times or higher than normal level;
- Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV)
criteria for benzodiazepine abuse or dependence within the past 6 months;
- DSM-IV criteria for alcohol dependence within the past 6 months;
- Actively suicidal;
- Psychiatric impairment that impedes ability to consent (dementia, delusional,
actively psychotic);
- Methadone dose exceeding levels allowing for safe transition to buprenorphine;
- Pregnant women and women actively trying to become pregnant;
- Clinical judgment of local site principal investigator that patient is inappropriate |
|
|
|
| Study is available at: |
|
Yale AIDS Program
New Haven, CT 06510
United States
Primary Contact:
Angela Acosta
Email: angela.acosta@yale.edu
Phone: 203-376-0221 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|